OOIR: Observatory of International Research

Papers

(The median citation count of CTS-Clinical and Translational Science is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients	290
A systematic review of micro‐RNAs in aortic stenosis and cardiac fibrosis	130
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan	96
How can real‐world evidence aid decision making during the life cycle of nonprescription medicines?	66
Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies	62
	62
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors	57
New Insights Into Hepatic Impairment (HI) Trials	51
Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial	51
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	49
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	44
A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults	43
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence	42
Effect of a Supratherapeutic Dose of Omaveloxolone on the Corrected QT Interval in Healthy Participants: A Randomized, Double‐Blind, Placebo‐ and Active‐Controlled, Three‐Way Crossover Stud	38
Modeling the Interplay Between Viral and Immune Dynamics in HIV: A Review and Mrgsolve Implementation and Exploration	37
Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome	36
Global Trends in the Value of Author Order Across Medical Publications: A Cross‐Sectional Bibliometric Study	34
Issue Information	34
National Prescribing Practices for Pediatric Dystonia Among Providers in the United States	33
AI In Action: Redefining Drug Discovery and Development	32
CYP2D6 genotype and associated 5‐HT₃ receptor antagonist outcomes: A systematic review and meta‐analysis	32
Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective	31
Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects	30
Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males	28
Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies	28

Pharmacometabolomics identifies candidate predictor metabolites of an L‐carnitine treatment mortality benefit in septic shock	28
Pharmacogenetic testing among patients with depression in a US managed care population	26
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia	26
Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose	25
Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval	25
Issue Information	25
TXNDC12 knockdown promotes ferroptosis by modulating SLC7A11 expression in glioma	24
Impact of NFIB and CYP1A variants on clozapine serum concentration—A retrospective naturalistic cohort study on 526 patients with known smoking habits	24
Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets	23
Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in heal	23
Response to “Wearable Remote Monitoring and COVID‐19”	23
Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response	22
Expression of Concern: Liu, X., Zhong, L., Li, P., & Zhao, P. MicroRNA‐100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4‐Depe	22
Evaluation of population‐level pharmacogenetic actionability in Alabama	22
	22
Evidence–time dilemma in a pandemic with high mortality: Can outcome‐driven decision making on vaccines prevent deaths?	22
Immune responsiveness in stable kidney transplantation patients: Complete inhibition of T‐cell proliferation but residual T‐cell activity during maintenance immunosuppressive treatment	21
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?	21
The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239	20
Issue Information	20
Evidence of depot‐specific regulation of all‐trans‐retinoic acid biosynthesis in human adipose tissue	20
MVP enhances FGF21‐induced ferroptosis in hepatocellular carcinoma by increasing lipid peroxidation through regulation of NOX4	20
Protective effect of clusterin against interleukin‐1β‐induced apoptosis and inflammation in human knee osteoarthritis chondrocytes	20
The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19	19
First‐in‐human development of a pharmacodynamic biomarker for PAC₁ receptor antagonists using intradermal injections of maxadilan	19
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens	19
Practical publication metrics for academics	19
A cross‐sectional survey on principal investigators' clinical research knowledge in Japan	18
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer	18
Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease	18
In memoriam Michelle A. Rudek (1972–2023)	18
	18
Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development	18
Expanding regulatory science: Regulatory complementarity and reliance	18
The effect of neuropsychiatric medication on pediatric nonalcoholic fatty liver disease	17
Twenty‐five years of addressing cutting‐edge scientific, policy, and regulatory issues through collaboration: The Forum for Collaborative Research	17
Closer to the patient means better decisions: wearable remote monitoring of patients with COVID‐19 lung disease	17
Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males	17
Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?	17
Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial)	16
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants	16
Model‐based dose selection to inform translational clinical oncology development of WNT974, a first‐in‐class Porcupine inhibitor	16
Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK)	16
Precision medicine in Asia enhanced by next‐generation sequencing: Implications for Thailand through a scoping review and interview study	16
Hydrogen sulfide donor protects against mechanical ventilation‐induced atrophy and contractile dysfunction in the rat diaphragm	16
Physiologically based absorption modeling to predict the bioequivalence of two cilostazol formulations	16
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data	16
NF1^+/ex42del miniswine model the cellular disruptions and behavioral presentations of NF1‐associated cognitive and motor impairment	16
Noninvasive assessment of carotid plaque with subharmonic aided pressure estimation from a US contrast agent: A preliminary study	16
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists	15

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients	15
Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta‐analysis	15
A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of ART‐001 with a novel oral pediatric formulation in healthy subjects	15
An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma	15
Using partition analysis as a facile method to derive net clearances	15
Adapting regulatory drug‐drug interaction guidance to design clinical pharmacokinetic natural product‐drug interaction studies: A NaPDI Center recommended approach	15
A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects	15
Preoperative medication use and development of postoperative delirium and cognitive dysfunction	15
Intradermal substance P as a challenge agent in healthy individuals	15
Randomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants	15
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization	14
Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan	14
	14
Safety, tolerability, and pharmacokinetics of single and multiple topical ophthalmic administration of imatinib mesylate in healthy subjects	14
A public–private collaboration model for clinical innovation	14
Integration of individual preclinical and clinical anti‐infective PKPD data to predict clinical study outcomes	14
Plerixafor for pathogen‐agnostic treatment in murine thigh infection and zebrafish sepsis	14
The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant	14
Digital health technology derived measures: Biomarkers or clinical outcome assessments?	14
Issue Information	14
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection	14
Issue Information	14
	13
Issue Information	13
Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis	13
Plasma sCD146 is a potential biomarker for acute exacerbation of chronic obstructive pulmonary disease	13
Differential effects of metformin‐mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial	13
Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin‐induced nephrotoxicity	13
Pharmacometabonomic association of cyclophosphamide 4‐hydroxylation in hematopoietic cell transplant recipients	13
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker	13
Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers	13
	13
Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers	12
Issue Information	12
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institution	12
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification	12
An implementation science focused practice‐based research network for rural community pharmacies: RURAL‐CP	12
Reply to “A call for reporting of tumor‐specific outcomes in studies of DPYD genotyping”	12
Issue Information	12
Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population	12
Association of liver fibrosis scores with all‐cause and cardiovascular mortality in patients with heart failure	12
Endogenous plasma riboflavin is not a viable BCRP biomarker in human	12
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document	12
Opportunities and challenges of 5G network technology toward precision medicine	12
Efficacy and safety of 4‐hydroxy 2‐methyl‐N‐(5‐methyl‐2‐thiazolyl)‐2H‐1, 2‐benzothiazin‐3‐carboxamide 1,1‐dioxide, a fast‐acting meloxicam formulation, on moderate‐to‐severe pain following abdominal s	12
Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized‐controlled trial	12
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach	11
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units	11
The safety and tolerability of levodopa eye drops for the treatment of ocular disorders: A randomized first‐in‐human study	11
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study	11
Persistent follicular granulosa cell senescence and apoptosis induced by methotrexate leading to oocyte dysfunction and aberrant embryo development	11
Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B	11
Development of immediate‐release formulation with reliable absorption of rivaroxaban in various meal regimes	11
Complex in vitro model: A transformative model in drug development and precision medicine	10
Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)	10
Corrigendum to: Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women	10
	10
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria	10
Clinical outcomes of generic versus brand‐name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study	10
Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2	10
Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison	10
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants	10
Dose‐dependent inactivation of airway tryptase with a novel dissociating anti‐tryptase antibody (MTPS9579A) in healthy participants: A randomized trial	10
Assessing the net financial benefits of employing digital endpoints in clinical trials	10
Corrigendum: First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor	10
Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug‐induced heart rate changes	10
Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events	10
Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients	10
Generalizability in real‐world trials	10
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development	10
Managing endothelial dysfunction in COVID‐19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double‐blind, placebo‐controlled, randomized clini	10
Antinuclear antibodies in COVID 19	10
A literature review of liver function test elevations in rifampin drug–drug interaction studies	10
Expression of Concern:Zhou, Y., & Zhou, J.Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and	10
Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects	10
Acute pharmacodynamic responses to sitagliptin: Drug‐induced increase in early insulin secretion in oral glucose tolerance test	10
Pediatric growth patterns in youth‐onset type 2 diabetes mellitus: Implications for physiologically‐based pharmacokinetic models	10
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications	10
CB‐HRNet: A Class‐Balanced High‐Resolution Network for the evaluation of endoscopic activity in patients with ulcerative colitis	10
Maribavir: Mechanism of action, clinical, and translational science	10

Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety	9
Correction to “Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers”	9
Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review	9
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study	9
Opportunities and challenges in translational science	9
Weight reduction added to CPAP decreases blood pressure and triglyceride level in OSA: Systematic review and meta‐analysis	9
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index	9
Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis	9
Pharmacogenomic landscape of Indian population using whole genomes	9
Correction to “Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary endpoints: A systematic review”	9
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts	9
Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers	9
Predicting complex kidney drug handling using a physiologically‐based pharmacokinetic model informed by biomarker‐estimated secretory clearance and blood flow	9
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin	9
Trends in oncology drug lags in Japan from 2001 to 2020: A cross‐sectional study	9
Pharmacodynamics of Aspirin Through Gestation: Predictors of Aspirin Response and Association With Pregnancy Outcome, a Prospective Cohort Study	9
Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T‐Cell Lymphoma	9
HLA‐associated adverse drug reactions ‐ scoping review	9
Natural intestinal metabolite xylitol reduces BRD4 levels to mitigate renal fibrosis	9
Relationship between blood glucose levels and length of hospital stay in patients with acute pancreatitis: An analysis of MIMIC‐III database	9
Effects of statins in patients with coronary artery spasm: A nationwide population‐based study	9
In vitro safety “clinical trial” of the cardiac liability of drug polytherapy	9
Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor	9
Concentration‐QTcF analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia	9
Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19	9
Analysis of the Korean generic medicine market: Factors affecting the market share of generic medicines	9
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community	9
First‐In‐Human Safety, Tolerability, and Pharmacokinetics of PPI‐1011, a Synthetic Plasmalogen Precursor	9
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence	9
Investigation of the Molecular Mechanisms of Paraoxonase‐2 Mediated Radiotherapy and Chemotherapy Resistance in Oral Squamous Cell Carcinoma	9
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	9
The needs and gaps in pharmacogenomics knowledge and education among healthcare professionals in Malaysia: A multisite Delphi study	9
Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”	9
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome	8
Serum cytokines to predict systemic lupus erythematosus clinical and serological activity	8
	8
Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects	8
Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial	8
Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: Implications for health inequities	8
A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia	8
Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions	8
Effects of triclabendazole and its metabolite exposure on the heart‐rate–corrected QT intervals: A randomized, placebo‐ and positive‐controlled thorough QT study in healthy individuals	8
Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users	8
	8
Issue Information	8
A call to action: Issuing a diversity and inclusion challenge to research organizations	8
Inadequate representation of individuals of African ancestry in pharmacogenetics of tamoxifen research	8
Investigating the role of an immediate early gene FOS as a potential regulator of autophagic response to hypoglycemia in embryonic hypothalamic neurons	8
Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies	8
	8
Association of concomitant headache with hypoperfusion in ischemic stroke: A multimodal CT‐based study	8
A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib	8
Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model	8
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters	8
Social network analysis of the CaRE² health equity center: Team science in full display	8
Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling	7
Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment	7
Influence of 4‐week or 12‐week glucocorticoid treatment on metabolic changes in patients with active moderate‐to‐severe thyroid‐associated ophthalmopathy	7
Bioequivalence of two oral formulations of tebipenem pivoxil hydrobromide in healthy subjects	7
Phase I crossover study of DNA‐protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension	7
The motivation and process for developing a consortium‐wide time and motion study to estimate resource implications of innovations in the use of genome sequencing to inform patient care	7
The National Heart, Lung, and Blood Institute‐funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy	7
Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery	7
First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator	7
A population pharmacodynamic Markov mixed‐effects model for determining remimazolam‐induced sedation when co‐administered with fentanyl in procedural sedation	7
Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants	7
Positive association between research competitiveness of Chinese academic hospitals and the scale of their biobanks: A national survey	7
Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVID‐19 pandemic	7
Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data	7
Induction of CD8⁺ immune memory and enhanced inflammation in a skin inflammation model through pre‐immunization with inactivated pathogens	7
How translational modeling in oncology needs to get the mechanism just right	7
Safety assessment of a three‐dimensional‐printed autologous omentum patch: An application on the kidneys as a new treatment approach	7
Rationale and design for a pragmatic randomized trial to assess gene‐based prescribing for SSRIs in the treatment of depression	7
Machine learning identifies fatigue as a key symptom of fibromyalgia reflected in tyrosine, purine, pyrimidine, and glutaminergic metabolism	7
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis	7
Utility of the ¹³C‐pantoprazole breath test as a CYP2C19 phenotyping probe for children	7
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors	7
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations	7
	7
The evolving landscape of immunotherapy for the treatment of allergic conditions	7
Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU	7
Optimal resting heart rate and ascites‐related death in patients with cirrhosis and ascites using nonselective beta‐blockers (ORCA)	7
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy	7
Liquid biopsy‐based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer	6
Bioequivalence study of dacomitinib and Vizimpro® in healthy Chinese volunteers under fasting and fed conditions: A randomized, open‐label, single‐dose, crossover trial	6
Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector	6
	6
	6
Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine‐based approach in diverse healthcare systems	6
The necessary conduct: Exploratory multiregional clinical trials in East Asia	6
Issue Information	6
Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes	6
	6
Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model	6
First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers	6